| Literature DB >> 26184166 |
Giovanna Calabrese1, Raffaella Giuffrida2, Debora Lo Furno3, Nunziatina Laura Parrinello4,5, Stefano Forte6, Rosario Gulino7,8, Cristina Colarossi9, Luciana Rita Schinocca10, Rosario Giuffrida8, Venera Cardile11, Lorenzo Memeo12,13.
Abstract
The Low-Affinity Nerve Growth Factor Receptor (LNGFR), also known as CD271, is a member of the tumor necrosis factor receptor superfamily. The CD271 cell surface marker defines a subset of multipotential mesenchymal stromal cells and may be used to isolate and enrich cells derived from bone marrow aspirate. In this study, we compare the proliferative and differentiation potentials of CD271+ and CD271- mesenchymal stromal cells. Mesenchymal stromal cells were isolated from bone marrow aspirate and adipose tissue by plastic adherence and positive selection. The proliferation and differentiation potentials of CD271+ and CD271- mesenchymal stromal cells were assessed by inducing osteogenic, adipogenic and chondrogenic in vitro differentiation. Compared to CD271+, CD271- mesenchymal stromal cells showed a lower proliferation rate and a decreased ability to give rise to osteocytes, adipocytes and chondrocytes. Furthermore, we observed that CD271+ mesenchymal stromal cells isolated from adipose tissue displayed a higher efficiency of proliferation and trilineage differentiation compared to CD271+ mesenchymal stromal cells isolated from bone marrow samples, although the CD271 expression levels were comparable. In conclusion, these data show that both the presence of CD271 antigen and the source of mesenchymal stromal cells represent important factors in determining the ability of the cells to proliferate and differentiate.Entities:
Keywords: CD271; adipogenic differentiation; adipose tissue; bone marrow; chondrogenic differentiation; mesenchymal stromal cells; osteogenic differentiation
Mesh:
Substances:
Year: 2015 PMID: 26184166 PMCID: PMC4519916 DOI: 10.3390/ijms160715609
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Flow cytometry results showing the percentage of cells expressing typical markers of mesenchymal stem cells.
| Marker | bmMSCCD271− (Mean ± s.e.m.) | bmMSCCD271+ (Mean ± s.e.m.) | adMSCCD271+ (Mean ± s.e.m.) | adMSCselCD271+ (Mean ± s.e.m.) | One-Way ANOVA | |
|---|---|---|---|---|---|---|
| 2.45 ± 0.55 | 7.08 ± 3.74 | 2.23 ± 0.92 | 5.13 ± 2.09 | 0.403 | 1.000 | |
| 2.30 ± 0.60 | 4.21 ± 1.67 | 2.93 ± 2.25 | 2.4 ± 1.6 | 0.824 | 1.000 | |
| 3.44 ± 2.10 | 5.17 ± 2.28 | 3.33 ± 1.94 | 3.83 ± 2.63 | 0.933 | 1.000 | |
| 88.13 ± 0.79 | 96.10 ± 2.41 | 87.00 ± 6.21 | 92.3 ± 6.17 | 0.513 | 1.000 | |
| 89.30 ± 2.72 | 82.33 ± 6.08 | 95.10 ± 1.75 | 94.13 ± 0.37 | 0.104 | 1.000 | |
| 88.10 ± 2.72 | 85.85 ± 6.08 | 88.43 ± 1.75 | 91.93 ± 1.68 | 0.77 | 1.000 | |
| 29.13 ± 8.18 | 78.83 ± 10.89 | 89.20 ± 5.66 | 90.57 ± 4.16 | 0.001 ** | 0.01 ** | |
| Tukey’s | ||||||
| adMSCselCD271+
| 1.366667 | −33.32805 | 36.06138 | 0.999 | ||
| bmMSCCD271−
| −60.066667 | −94.76138 | −25.37195 | 0.002 ** | ||
| bmMSCCD271+
| −10.373333 | −45.06805 | 24.32138 | 0.776 | ||
| bmMSCCD271−
| −61.433333 | −96.12805 | −26.73862 | 0.002 ** | ||
| bmMSCCD271+
| −11.740000 | −46.43471 | 22.95471 | 0.708 | ||
| bmMSCCD271+
| 49.693333 | 14.99862 | 84.38805 | 0.007 ** | ||
Immunopositive cellular fractions for several surface marker assessed by flow cytometry are shown for each cell type. In the top table the statistical significance of percentages differences among the three groups, assessed by one-way ANOVA, is reported in the last two columns (raw and Bonferroni corrected p values respectively). CD271 is the only surface marker that shows statistically significant differences. Post-hoc pairwise comparisons of CD271 percentages, performed using Tukey’s method, is summarized in the bottom table. Significant differences are observed only between bmMSCCD271− and bmMSCCD271+, between bmMSCCD271− and adMSCCD271+, as well as between bmMSCCD271− and adMSCselCD271+. ** p < 0.01.
Figure 1Flow cytometry expression of CD271 in bmMSCCD271−, bmMSCCD271+, adMSCCD271+ and adMSCselCD271+ lines; (a) Representative histograms of only one for each type of the four different cell lines; (b) Average Percentage of CD271+ cells in the four different cell types.
Figure 2DAPI staining showing the cell density at different time points after osteogenic differentiation. (a) Representative DAPI staining of bmMSCCD271−, bmMSCCD271+ and adMSCCD271+ at the 24th day of differentiation; (b) Similarly, cell count shows statistically significant differences among cell lines at day 8, 16 and 24 (p = 0.0497). In particular, data clearly show that CD271+ MSCs have a higher proliferation rate as compared to CD271− MSCs, with statistical significance maintained in adMSCCD271+ vs. bmMSCCD271− pairwise comparison (p = 0.0381). * p < 0.05.
Figure 3Oil-Red O staining of bmMSCCD271−, bmMSCCD271+ and adMSCCD271+ after 7, 14 and 28 days of adipogenic differentiation.
Figure 4Alizarin Red staining of bmMSCCD271−, bmMSCCD271+ and adMSCCD271+ after 8, 16 and 24 days of osteogenic induction.
Figure 5Alcian blue staining of bmMSCCD271−, bmMSCCD271+ and adMSCCD271+ after 7, 14 and 28 days of chondrogenic differentiation.
Table summarizing the cell origin and the clinical data of donor patients.
| Donor | Age | Sex | Sources | Disease | Diagnosis | Follow-up |
|---|---|---|---|---|---|---|
| 66 | M | Aspirate | CHL | Post-chemiotherapy | Healthy | |
| 70 | M | Aspirate | CML | Post-chemiotherapy | Healthy | |
| 64 | F | Aspirate | CML | Onset | Healthy | |
| 62 | M | Kidney | – | No chemiotherapy | Healthy | |
| 61 | F | Breast | – | No chemiotherapy | Healthy | |
| 60 | F | Colon | – | No chemiotherapy | Healthy |
CHL, Classical Hodgkin’s Lymphoma; CML, Chronic Myelogenous Leukemia.